The actively developing Cancer Prevention and Control Program (CPCP) at the Fred & Pamela Buffett Cancer Center endeavors to support our interdisciplinary teams of preclinical, clinical and translational scientists to achieve national and international leadership in: 1) identifying and mitigating biologic, behavioral, and social factors that increase susceptibility to cancer; and 2) reducing cancer burden in patients and communities through novel and rigorous scientific approaches that identify and modulate biopsychosocial factors, treatments, and symptom assessment and management strategies.
CPCP scientists will lead in the following areas across the cancer continuum:
- Prevention - Exploration of cancer etiology, genetics, and biomarkers of cancer susceptibility will inform behavioral and environmental science on cancer risk and prevention.
- Early detection & treatment - Social determinants of health, health inequities, person, environmental, biological, genetic, imaging and system factors will be identified, and interventions tested, to remove barriers to screening, genetic testing, and early initiation of cancer treatment
- Survivorship - Basic, clinical, and behavioral scientists will lead in the development of cancer mitigating treatments and interventions to reduce physical and psychosocial symptoms and support wellness of patients and caregivers from diagnosis to end of life.
Program Leaders:
 |
Raymond Bergan, MD |
 |
Robin M. Lally, PhD, MS, RN, AOCN, FAAN |
 |
Quan Ly, MD FACS |
 |
Rachael Schmidt, DNP, APRN, AOCNP |
 |
Shinobu Watanabe-Galloway, PhD |